{"id":452356,"date":"2021-03-08T07:03:22","date_gmt":"2021-03-08T12:03:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452356"},"modified":"2021-03-08T07:03:22","modified_gmt":"2021-03-08T12:03:22","slug":"athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/","title":{"rendered":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOTHELL, Wash., March  08, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=maHN3jClToYLm0e7RZGlW66DP2ECSxvjRJ8DL9AjuTVEEBqJZqHiIQ69x-lc39xGWv_HmyB9EOaYEGwoQc5IgA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Athira Pharma, Inc.<\/a> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer.<\/p>\n<p>\u201cBarbara will add to the existing expertise of our Board, bringing her vast experience in working strategically with biopharma companies and adding a new perspective to our team as we continue to advance our clinical trials and drug-development platform,\u201d said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. \u201cThe diverse backgrounds and experience of our Board in science, medicine, and business are highly complementary to our innovative company vision.\u201d<\/p>\n<p>Ms. Kosacz is universally recognized as one of the top life sciences attorneys in the country. With more than 25 years of experience providing strategic business and legal counsel, Ms. Kosacz has led some of the most complex and transformational transactions in the life sciences industry. Her experience includes counseling clients in the life sciences industry, ranging from early-stage startups to larger public companies, venture funds, investment banks, and non-profit institutions.<\/p>\n<p>Ms. Kosacz commented: &#8220;Athira has a unique drug development platform with promising product opportunities, and I\u2019m pleased to become involved at this exciting time. I\u2019m passionate about my work in counseling biotechnology companies that are dedicated to improving outcomes for patients, and I look forward to helping guide the company as it continues to grow.\u201d<\/p>\n<p>Ms. Kosacz has been Chief Operating Officer and General Counsel at Kronos Bio since July 2020. Prior to joining Kronos Bio, she was Partner and Head of the International Life Sciences Practice at Cooley LLP, a leading international law firm. During her tenure at Cooley, Ms. Kosacz received significant recognition for her role in the industry, including being recognized as Biotechnology Lawyer of the Year in 2018 by <em>Best Lawyers in America<\/em> and as a highly recommended transactions lawyer by IAM Patent 1000 for her \u201cnearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.\u201d Ms. Kosacz serves on the Board of Directors of XOMA Corp. and Locust Walk Acquisition Corporation (a SPAC), and the Board of Trustees of the Keck Graduate Institute. Ms. Kosacz received a bachelor\u2019s degree from Stanford University and a JD from the University of California, Berkeley School of Law.<\/p>\n<p>\n        <strong>About Athira Pharma, Inc.<\/strong><br \/>\n        <br \/>Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Eagf5iMXn-BFCGL3aCPv0R-R5Cd10dtaipaCnrpayMOFuWRvk8SPX0axXweLtEy2uv5TfmZo-bSttkGMX1EiQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.athira.com<\/a>. You can also follow Athira on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HYMgJVAzI49caArP4YDHhdbo2WlYhxaFhWRgrtmVyUfmCtvI2XhxAtia5-9zsXwtRtYZ5_O-Sq8Ij9Mz10WWnkiWVaIaZLD1FBTQ2uluQYA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tNIh6LahxoYWQwyticbKTQx5mxzyB_9lprseqbz9H0D5YHu1QbeMPRBzRXxlv6oPZ5FIjH_iCQgzOxcfbBn70gLQpPsgEU0KqDFP8KHmync=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0@athirapharma on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wk3RVEwg38razG5UIJGR5J4GdJ2Pz5RWR9kfznkCi-OEKgDb6HtmveDTXL8i7l4IynhiFaokJvaoF2zX6nRHrGfbMukyTcnoq68dygGMJXE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gXyfLzc-1CWPDVsLsmDLa6hWRVYOG7QHTRQtZ9d9d2uBnhi-i4tMNOZes0nvOHqeaF5BBW-DT1OTWt8gT6Y10ABeAAMaCfpOblrj209oWqI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer\u2019s disease and other dementias; Athira\u2019s platform technology and potential therapies; future development plans; clinical and regulatory objectives; expectations regarding the potential efficacy and commercial potential of Athira\u2019s product candidates, including ATH-1017; the results of Athira\u2019s research and development efforts and Athira\u2019s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words and phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;pursue,&#8221; \u201ccontinue,\u201d and other similar expressions, among others. Any forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira\u2019s ATH-1017 product candidate from the Phase 1a\/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and\/or Athira\u2019s development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira\u2019s business; Athira\u2019s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira\u2019s product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks detailed in Athira\u2019s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact<\/strong>: <br \/>Julie Rathbun<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iqJvusP1YFDpPrNE8zfFum4-rDaIssl0D8ac5G-8urVUMhgYzd6l3zcpYZQ92_n9C6OmhE3iWHhtaZljfR1sZjoiaJahTb-18CAhXcUrqRw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Julie.rathbun@athira.com<\/a><br \/>206-769-9219<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/49210349-3e65-4d27-8a60-fd858a26c7ba\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer. \u201cBarbara will add to the existing expertise of our Board, bringing her vast experience in working strategically with biopharma companies and adding a new perspective to our team as we continue to advance our clinical trials and drug-development platform,\u201d said Leen Kawas, Ph.D., President and Chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452356","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer. \u201cBarbara will add to the existing expertise of our Board, bringing her vast experience in working strategically with biopharma companies and adding a new perspective to our team as we continue to advance our clinical trials and drug-development platform,\u201d said Leen Kawas, Ph.D., President and Chief &hellip; Continue reading &quot;Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T12:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors\",\"datePublished\":\"2021-03-08T12:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/\"},\"wordCount\":929,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/\",\"name\":\"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\",\"datePublished\":\"2021-03-08T12:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk","og_description":"BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Board of Directors. Ms. Kosacz is Chief Operating Officer and General Counsel at Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that transform the lives of those affected by cancer. \u201cBarbara will add to the existing expertise of our Board, bringing her vast experience in working strategically with biopharma companies and adding a new perspective to our team as we continue to advance our clinical trials and drug-development platform,\u201d said Leen Kawas, Ph.D., President and Chief &hellip; Continue reading \"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T12:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors","datePublished":"2021-03-08T12:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/"},"wordCount":929,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/","name":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=","datePublished":"2021-03-08T12:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NTYyOCM0MDUxNzIzIzIyMDE4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma Announces Appointment of Barbara Kosacz\u00a0to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452356"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}